CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results

CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings results on Tuesday. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41, Briefing.com reports. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter last year, the firm earned ($1.41) earnings per share.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded down $0.24 during mid-day trading on Friday, reaching $51.64. 652,718 shares of the company traded hands, compared to its average volume of 1,452,756. CRISPR Therapeutics has a 52-week low of $43.42 and a 52-week high of $91.10. The firm has a market capitalization of $4.39 billion, a price-to-earnings ratio of -16.06 and a beta of 1.67. The firm’s 50 day moving average price is $47.38 and its 200 day moving average price is $52.24.

Wall Street Analyst Weigh In

Several equities analysts recently commented on CRSP shares. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Thursday. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday. Barclays lowered their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday. Finally, Rodman & Renshaw started coverage on shares of CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 price objective for the company. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $74.94.

Insider Activity

In other news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares in the company, valued at approximately $10,484,271.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.